Iron deficiency in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
暂无分享,去创建一个
G. Pontone | G. Muscogiuri | M. Trinei | G. Marenzi | A. Baggiano | M. Guglielmo | A. Bartorelli | M. Sandri | J. Campodonico | A. Bonomi | D. Riggio | N. Cosentino | M. Moltrasio | G. Lauri | S. Barbieri | V. Milazzo | E. Assanelli | Simone Barbieri
[1] D. Andreini,et al. Association Between Haptoglobin Phenotype and Microvascular Obstruction in Patients With STEMI: A Cardiac Magnetic Resonance Study. , 2019, JACC. Cardiovascular imaging.
[2] R. Schnabel,et al. Adverse Outcome Prediction of Iron Deficiency in Patients with Acute Coronary Syndrome , 2018, Biomolecules.
[3] D. Swinkels,et al. Definition of Iron Deficiency Based on the Gold Standard of Bone Marrow Iron Staining in Heart Failure Patients , 2018, Circulation. Heart failure.
[4] Y. Konstantinov,et al. The level of free circulating mitochondrial DNA in blood as predictor of death in case of acute coronary syndrome , 2017, European Journal of Medical Research.
[5] G. Dorn,et al. Mitochondrial Function, Biology, and Role in Disease: A Scientific Statement From the American Heart Association. , 2016, Circulation research.
[6] J. Comín-Colet,et al. Déficit de hierro en pacientes con síndrome coronario agudo: prevalencia y factores predisponentes , 2016 .
[7] D. Andreini,et al. Myocardial Infarct Size in Patients on Long-Term Statin Therapy Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. , 2015, The American journal of cardiology.
[8] Lijun Wang,et al. Plasma nuclear and mitochondrial DNA levels in acute myocardial infarction patients , 2015, Coronary artery disease.
[9] A. Cohen-Solal,et al. High prevalence of iron deficiency in patients with acute decompensated heart failure , 2014, European journal of heart failure.
[10] C. Kuo,et al. Serum Iron Concentration, but Not Hemoglobin, Correlates with TIMI Risk Score and 6-Month Left Ventricular Performance after Primary Angioplasty for Acute Myocardial Infarction , 2014, PloS one.
[11] R. Bueno,et al. Circulating Mitochondrial DNA in Patients in the ICU as a Marker of Mortality: Derivation and Validation , 2013, PLoS medicine.
[12] G. Niccoli,et al. Microvascular obstruction after primary percutaneous coronary intervention: pathogenesis, diagnosis and prognostic significance. , 2013, Current vascular pharmacology.
[13] P. Ponikowski,et al. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives , 2012, European heart journal.
[14] P. Ponikowski,et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study , 2012, European heart journal.
[15] E. López-Collazo,et al. Circulating cell-free mitochondrial DNA: a better early prognostic marker in patients with out-of-hospital cardiac arrest. , 2012, Resuscitation.
[16] G. Andersen,et al. Increased circulating mitochondrial DNA after myocardial infarction. , 2012, International journal of cardiology.
[17] J. Holst,et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. , 2012, European heart journal.
[18] A. Dart,et al. Effect of Iron Chelation on Myocardial Infarct Size and Oxidative Stress in ST-Elevation–Myocardial Infarction , 2012, Circulation. Cardiovascular interventions.
[19] Sunil K. Kakarla,et al. Iron-Induced Cardiac Damage: Role of Apoptosis and Deferasirox Intervention , 2011, Journal of Pharmacology and Experimental Therapeutics.
[20] A. Kastrati,et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. , 2010, Journal of the American College of Cardiology.
[21] M. Núñez,et al. Iron induces protection and necrosis in cultured cardiomyocytes: Role of reactive oxygen species and nitric oxide. , 2010, Free radical biology & medicine.
[22] E. Ruokonen,et al. Cell-free plasma DNA as a predictor of outcome in severe sepsis and septic shock. , 2008, Clinical chemistry.
[23] Richard F Hurrell,et al. Nutritional iron deficiency , 2007, The Lancet.
[24] F. Veglia,et al. Impact of cardiac and renal dysfunction on inhospital morbidity and mortality of patients with acute myocardial infarction undergoing primary angioplasty. , 2007, American heart journal.
[25] P. Bernardi,et al. Mitochondria and ischemia-reperfusion injury of the heart: fixing a hole. , 2006, Cardiovascular research.
[26] K. Pantopoulos,et al. Iron metabolism and toxicity. , 2005, Toxicology and applied pharmacology.
[27] Y. Lo,et al. Prognostic use of circulating plasma nucleic acid concentrations in patients with acute stroke. , 2003, Clinical chemistry.
[28] J. Boura,et al. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction : a quantitative review of 23 randomised trials , 2022 .
[29] A. Hofman,et al. Iron status in the acute phase and six weeks after myocardial infarction. , 1990, Free radical biology & medicine.
[30] M. Weisfeldt,et al. Improvement of postischemic myocardial function and metabolism induced by administration of deferoxamine at the time of reflow: the role of iron in the pathogenesis of reperfusion injury. , 1987, Circulation.